Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Phase 2b, randomized, double‐blinded, placebo‐controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1‐4 comprising Part 1, and dosing Groups 5‐6 comprising Part 2. All subjects will receive open‐label ISB 830 after a 16 week blinded treatment period.
Epistemonikos ID: f78e59ddf09efc7bd4e7d1b887129324c54af195
First added on: May 21, 2024